These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

958 related items for PubMed ID: 30132104

  • 1. 68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study.
    Dyrberg E, Hendel HW, Huynh THV, Klausen TW, Løgager VB, Madsen C, Pedersen EM, Pedersen M, Thomsen HS.
    Eur Radiol; 2019 Mar; 29(3):1221-1230. PubMed ID: 30132104
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Mar; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer.
    Zacho HD, Nielsen JB, Afshar-Oromieh A, Haberkorn U, deSouza N, De Paepe K, Dettmann K, Langkilde NC, Haarmark C, Fisker RV, Arp DT, Carl J, Jensen JB, Petersen LJ.
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1884-1897. PubMed ID: 29876619
    [Abstract] [Full Text] [Related]

  • 4. Whole-Body Integrated [68Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference.
    Guberina N, Hetkamp P, Ruebben H, Fendler W, Grueneisen J, Suntharalingam S, Kirchner J, Puellen L, Harke N, Radtke JP, Umutlu L, Hadaschik BA, Herrmann K, Forsting M, Wetter A.
    Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
    Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG, proPSMA Study Group Collaborators.
    Lancet; 2020 Apr 11; 395(10231):1208-1216. PubMed ID: 32209449
    [Abstract] [Full Text] [Related]

  • 6. A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer.
    Harmon SA, Bergvall E, Mena E, Shih JH, Adler S, McKinney Y, Mehralivand S, Citrin DE, Couvillon A, Madan RA, Gulley JL, Mease RC, Jacobs PM, Pomper MG, Turkbey B, Choyke PL, Lindenberg ML.
    J Nucl Med; 2018 Nov 11; 59(11):1665-1671. PubMed ID: 29602821
    [Abstract] [Full Text] [Related]

  • 7. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE).
    Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, Rinta-Kiikka I, Schildt J, Saukko E, Rautio P, Timonen KL, Matikainen T, Noponen T, Saunavaara J, Löyttyniemi E, Taimen P, Kemppainen J, Dean PB, Blanco Sequeiros R, Aronen HJ, Seppänen M, Boström PJ.
    Eur Urol Oncol; 2021 Aug 11; 4(4):635-644. PubMed ID: 32675047
    [Abstract] [Full Text] [Related]

  • 8. Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy.
    Uprimny C, Svirydenka A, Fritz J, Kroiss AS, Nilica B, Decristoforo C, Haubner R, von Guggenberg E, Buxbaum S, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2018 Oct 11; 45(11):1873-1883. PubMed ID: 29766246
    [Abstract] [Full Text] [Related]

  • 9. Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy.
    Nikitas J, Gafita A, Benz MR, Djaïleb L, Farolfi A, Hotta M, Sonni I, Alano R, Rettig M, Shen J, Armstrong W, Grogan T, Liu S, Czernin J, Calais J.
    Sci Rep; 2024 Oct 18; 14(1):24411. PubMed ID: 39420060
    [Abstract] [Full Text] [Related]

  • 10. Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study.
    Domachevsky L, Bernstine H, Goldberg N, Nidam M, Catalano OA, Groshar D.
    Eur Radiol; 2020 Jan 18; 30(1):328-336. PubMed ID: 31332559
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic bone imaging in patients with prostate cancer: patient experience and acceptance of NaF-PET/CT, choline-PET/CT, whole-body MRI, and bone SPECT/CT.
    Dyrberg E, Larsen EL, Hendel HW, Thomsen HS.
    Acta Radiol; 2018 Sep 18; 59(9):1119-1125. PubMed ID: 29313360
    [Abstract] [Full Text] [Related]

  • 12. A Prospective Study Comparing 99mTc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with 18F-Fluoride PET/CT and 18F-Fluoride PET/MRI for Diagnosing Bone Metastases.
    Löfgren J, Mortensen J, Rasmussen SH, Madsen C, Loft A, Hansen AE, Oturai P, Jensen KE, Mørk ML, Reichkendler M, Højgaard L, Fischer BM.
    J Nucl Med; 2017 Nov 18; 58(11):1778-1785. PubMed ID: 28798033
    [Abstract] [Full Text] [Related]

  • 13. Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients.
    Schilham MGM, Zamecnik P, Privé BM, Israël B, Rijpkema M, Scheenen T, Barentsz JO, Nagarajah J, Gotthardt M.
    J Nucl Med; 2021 Sep 01; 62(9):1258-1263. PubMed ID: 33517328
    [Abstract] [Full Text] [Related]

  • 14. Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy.
    Sawicki LM, Kirchner J, Buddensieck C, Antke C, Ullrich T, Schimmöller L, Boos J, Schleich C, Schaarschmidt BM, Buchbender C, Heusch P, Rabenalt R, Albers P, Antoch G, Müller HW, Hautzel H.
    Eur J Nucl Med Mol Imaging; 2019 Jul 01; 46(7):1542-1550. PubMed ID: 30879122
    [Abstract] [Full Text] [Related]

  • 15. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
    Johnston EW, Latifoltojar A, Sidhu HS, Ramachandran N, Sokolska M, Bainbridge A, Moore C, Ahmed HU, Punwani S.
    Eur Radiol; 2019 Jun 01; 29(6):3159-3169. PubMed ID: 30519933
    [Abstract] [Full Text] [Related]

  • 16. Hybrid Ga-68 prostate-specific membrane antigen PET/MRI in the detection of skeletal metastasis in patients with newly diagnosed prostate cancer: Contribution of each part to the diagnostic performance.
    Asa S, Ozgur E, Uslu-Besli L, Ince B, Sager S, Demirdag C, Guner E, Sayman HB, Bakir B, Sonmezoglu K.
    Nucl Med Commun; 2023 Jan 01; 44(1):65-73. PubMed ID: 36378618
    [Abstract] [Full Text] [Related]

  • 17. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.
    Zhou J, Gou Z, Wu R, Yuan Y, Yu G, Zhao Y.
    Skeletal Radiol; 2019 Dec 01; 48(12):1915-1924. PubMed ID: 31127357
    [Abstract] [Full Text] [Related]

  • 18. Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.
    Rowe SP, Li X, Trock BJ, Werner RA, Frey S, DiGianvittorio M, Bleiler JK, Reyes DK, Abdallah R, Pienta KJ, Gorin MA, Pomper MG.
    J Nucl Med; 2020 Feb 01; 61(2):183-188. PubMed ID: 31451492
    [Abstract] [Full Text] [Related]

  • 19. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
    Amin A, Blazevski A, Thompson J, Scheltema MJ, Hofman MS, Murphy D, Lawrentschuk N, Sathianathen N, Kapoor J, Woo HH, Chalasani V, Rasiah K, van Leeuwen PJ, Tang R, Cusick T, Stricker P, Emmett L.
    BJU Int; 2020 Apr 01; 125(4):515-524. PubMed ID: 31957122
    [Abstract] [Full Text] [Related]

  • 20. Observer Agreement and Accuracy of 18F-Sodium Fluoride PET/CT in the Diagnosis of Bone Metastases in Prostate Cancer.
    Zacho HD, Fonager RF, Nielsen JB, Haarmark C, Hendel HW, Johansen MB, Mortensen JC, Petersen LJ.
    J Nucl Med; 2020 Mar 01; 61(3):344-349. PubMed ID: 31481577
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.